...
首页> 外文期刊>Journal of Medicinal Chemistry >Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.
【24h】

Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.

机译:包含苄氧基取代的苯甲酰基肽模拟物的组织蛋白酶K抑制剂的基于结构的设计。

获取原文
获取原文并翻译 | 示例

摘要

Peptidomimetic cathepsin K inhibitors have been designed using binding models which were based on the X-ray crystal structure of an amino acid-based, active site-spanning inhibitor complexed with cathepsin K. These inhibitors, which contain a benzyloxybenzoyl group in place of a Cbz-leucine moiety, maintained good inhibitory potency relative to the amino acid-based inhibitor, and the binding models were found to be very predictive of relative inhibitor potency. The binding mode of one of the inhibitors was confirmed by X-ray crystallography, and the crystallographically determined structure is in close qualitative agreement with the initial binding model. These results strengthen the validity of a strategy involving iterative cycles of structure-based design, inhibitor synthesis and evaluation, and crystallographic structure determination for the discovery of peptidomimetic inhibitors.
机译:使用结合模型设计了拟肽组织蛋白酶K抑制剂,该模型基于与组织蛋白酶K复合的基于氨基酸的活性位点跨越抑制剂的X射线晶体结构。这些抑制剂包含苄氧基苯甲酰基代替Cbz -亮氨酸部分,相对于基于氨基酸的抑制剂而言,保持了良好的抑制效能,并且发现结合模型非常可预测相对抑制剂的效能。通过X射线晶体学证实了一种抑制剂的结合模式,并且晶体学确定的结构与初始结合模型在质量上紧密一致。这些结果加强了一种策略的有效性,该策略涉及基于结构的设计,抑制剂合成和评估以及确定拟肽抑制剂发现的晶体学结构的迭代循环。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号